Theriva Biologics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
TOVX$0.15-7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholder’s Equity
(In thousands, except share and par value amounts)
| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock $0.001 Par Value · · · · · · · · Accumulated · · · · · | |||||||||||||||||||
| · · · · · · · Additional · · · · Other · · · · Total | |||||||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Comprehensive · · · · Stockholders’ | |||||||||||||||||||
| · Shares · Amount · Capital · Deficit · Income · Treasury Stock · Equity | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2022 | 634,069 | | $1 | $343,765 | | $(290,969) | | $(679) | | (288) | | $51,830 | |||||||
| | | | | | | | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | 552 | | — | | — | | — | | 552 | ||||||
| Stock issued under “at-the-market” offering | 80,959 | | — | | 2,219 | | — | | — | | — | | 2,219 | ||||||
| Foreign currency exchange gains | — | | — | | — | | — | | 711 | | — | | 711 | ||||||
| Net loss | | — | | | — | | | — | | | (18,349) | | | — | | — | | | (18,349) |
| | | | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2023 | 715,028 | | $1 | $346,536 | | $(309,318) | | $32 | | (288) | | $36,963 | |||||||
| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock $0.001 Par Value · · · · · · · · Accumulated · · · · · | |||||||||||||||||||
| · · · · · · · Additional · · · · · Other · · · · Total | |||||||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Comprehensive · · · · Stockholders’ | |||||||||||||||||||
| · Shares · Amount · Capital · Deficit · Loss · Treasury Stock · Equity | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2023 | 715,028 | | $1 | | $346,536 | | $(309,318) | | $32 | (288) | | $36,963 | |||||||
| | | | | | | | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | 671 | | — | | — | — | | 671 | |||||||
| Stock issued under “at-the-market” offering | 569,282 | | 1 | | 3,602 | | — | | — | — | | 3,603 | |||||||
| Issuance of Common Stock and Warrants, net of issuance costs | | 918,600 | | | 1 | | | 1,959 | | | — | | | — | | — | | | 1,960 |
| Series C Preferred Stock conversion to Common | | 72,132 | | | — | | | 2,005 | | | — | | | — | | — | | | 2,005 |
| Series D Preferred Stock conversion to Common | | 26,230 | | | — | | | 728 | | | — | | | — | | — | | | 728 |
| Conversion of Pre-Funded Warrants to Common | 509,987 | | — | | — | | — | | — | — | | — | |||||||
| Foreign currency exchange loss | — | | — | | — | | — | | (1,210) | — | | (1,210) | |||||||
| Net loss | — | | — | | — | | (25,653) | | — | — | | (25,653) | |||||||
| | | | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2024 | 2,811,259 | | $3 | | $355,501 | | $(334,971) | | $(1,178) | (288) | | $19,067 | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.